Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
My Lists

Infinity Pharmaceuticals  (Stock symbol: INFI )

780 Memorial Drive
Cambridge, MA 2139

Website Company Summary Management Team

Management: Adelene Perkins (CEO);  Julian Adams (President);  Vito Palombella (Chief Scientific Officer)
Former Management Team:  Gautam Kollu
Business Description

Infinity Pharmaceuticals, Inc. (IPI) is a drug discovery and development company. The Company's lead product candidate, IPI-504 (retaspimycin hydrochloride), is an intravenously administered small molecule inhibitor of heat shock protein 90 (Hsp90). Hsp90 is a central component of the cellular chaperone system-a system that supports and stabilizes cancer-causing proteins, such as epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), enabling multiple forms of cancer to thrive. Inhibition of the Hsp90 chaperone knocks out this critical source of support for cancer cells, leading to tumor growth inhibition and cancer cell death.
Customer on 1  Companies

Partner on 1  Companies

Last Tweets


Last Mentions

Record updated: Sep 2010
Ownership: Public  
Stock Symbol: INFI